Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial

European Journal of Cancer

Volumn 48, Issue 1, 2012, Pages 37-45

  Kennecke, Hagen ^a   Berry, Scott ^b   Wong, Ralph ^c   Zhou, Chen ^a   Tankel, Keith ^d   Easaw, Jacob ^e   Rao, Sanjay ^a   Post, Jacqueline ^f   Hay, John ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c ST BONIFACE GENERAL HOSPITAL   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e Tom Baker Cancer Institute   (Canada)

^f Ozmosis Research Inc   (Canada)

Author keywords

Bevacizumab; Capecitabine; Locally advanced rectal cancer; Oxaliplatin; Phase II trial; Radiotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS LEAKAGE; ANOREXIA; ARTICLE; BLEEDING; CANCER LOCALIZATION; CANCER REGRESSION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEMALE; FISTULA; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEALING IMPAIRMENT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; MALE; MOOD CHANGE; MULTICENTER STUDY; NAUSEA; PAIN; PATIENT SAFETY; PELVIC DISEASE; PERFORATION; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROCTITIS; RADIATION DOSE; RADIATION INJURY; RASH; RECTUM CANCER; RECTUM RESECTION; REOPERATION; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT OUTCOME; URINARY URGENCY; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; COLORECTAL SURGERY; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE PERIOD; RECTAL NEOPLASMS; TIME FACTORS;

EID: 83255194188     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.05.016     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. http://www.globocan.iarc.fr.
2. J.E. Tepper, M. O'Connell, and D. Niedzwiecki Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of intergroup 0114 J Clin Oncol 20 2002 1744 1750
3. S.R. Smalley, J.K. Benedetti, and S.K. Williamson Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144 J Clin Oncol 24 2006 3542 3547
4. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
5. T. André, C. Boni, and L. Mounedji-Boudiaf Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351
6. J.P. Kuebler, H.S. Wieand, and M.J. O'Connell Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol 25 2007 2198 2204
7. E. Kapiteijn, C.A.M. Marijne, and I.D. Nagtegaal Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer N Eng J Med 345 2001 638 646
8. Libutti SK, Tepper JE, Saltz LB. Rectal cancer, In: DeVita VT, Lawrence TS, Rosenberg SA (Eds.), Cancer: principles and practice of oncology, 8th ed., Philadelphia, PA, Lippincott Williams and Wilkins, 2008, p. 1287-1301.
9. C. Rödel, T. Liersch, and R.M. Hermann Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer J Clin Oncol 25 2007 110 117
10. Cancer and Leukemia Group B 89901 D.P. Ryan, and D. Niedzwiecki Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: cancer and leukemia group B 89901 J Clin Oncol 24 2006 2557 2562
11. J.P. Gérard, D. Azria, and S. Gourgou-Bourgade Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2 J Clin Oncol 28 2010 1638 1644
12. C. Aschele, C. Pinto, and S. Cordio Preoperative fluorouracil (FU)-based chemoradiation with, without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial J Clin Oncol 27 2009 18s (suppl; abstr CRA4008)
13. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
14. N. Wolmark, G. Yothers, and M.J. O'Connell A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 J Clin Oncol 27 2009 18s (suppl; abstr LBA4)
15. http://www.roche.com/investors/irupdate/inv-update-2010-09-18b.html.
16. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
17. C.G. Willett, D.G. Duda, and E. di Tomaso Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study J Clin Oncol 27 2009 3020 3026
18. O. Dworak, L. Keilholz, and A. Hoffmann Pathological features of rectal cancer after preoperative radiochemotherapy Int J Colorectal Dis 12 1997 19 23
19. C. Ahn An evaluation of phase I cancer clinical trial designs Stat Med 17 1998 1537 1549
20. M. Maas, P.J. Nelemans, and V. Valentini Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol 11 2010 835 844
21. C. Rödel, P. Martus, and T. Papadoupolos Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer J Clin Oncol 23 2005 8688 8696
22. J.P. Gérard, T. Conroy, and F. Bonnetain Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 24 2006 4620 4625
23. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
24. J.F. Bosset, G. Calais, and L. Mineur Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921 J Clin Oncol 23 2005 5620 5627
25. R. Glynne-Jones, and D. Sebag-Montefiore Are we ready to use an early alternative end point as the primary end point of a phase III study in rectal cancer? J Clin Oncol 28 2010 e579 e580
26. E.A. Newman, A.B. Guest, and M.A. Helvie Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board Cancer 107 2006 2346 2351
27. C.H. Crane, C. Eng, and B.W. Feig Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer Int J Radiat Oncol Biol Phys 76 2010 824 830
28. K. Bujko, M.P. Nowacki, and L. Kepka Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs chemoradiation Colorectal Dis 7 2005 410 416
29. C. Fernández-Martos, C. Pericay, and J. Aparicio Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study J Clin Oncol 28 2010 859 865
30. Y.J. Chua, Y. Barbachano, and D. Cunningham Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial Lancet Oncol 11 2010 241 248